Luigi Portella

Naples, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications

CXCR4, CXCR7 and PBRM1 are responsible for everolimus and cabozantinib resistance in human renal cancer cells.

CXCR4, CXCR7 and PBRM1 are responsible for everolimus and cabozantinib resistance in human renal cancer cells.

Journal: Cell death discovery
Published: July 30, 2025

The CXCR4 antagonist R54 targets epithelial-mesenchymal transition (EMT) in human ovarian cancer cells.

The CXCR4 antagonist R54 targets epithelial-mesenchymal transition (EMT) in human ovarian cancer cells.

Journal: PloS one
Published: August 02, 2024

KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer.

KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 08, 2024

CXCL12-loaded-hydrogel (CLG): A new device for metastatic circulating tumor cells (CTCs) capturing and characterization.

CXCL12-loaded-hydrogel (CLG): A new device for metastatic circulating tumor cells (CTCs) capturing and characterization.

Journal: Heliyon
Published: September 26, 2023

Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients.

Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients.

Journal: British journal of cancer
Published: September 20, 2023

Hepatocellular carcinoma (HCC) tumor microenvironment is more suppressive than colorectal cancer liver metastasis (CRLM) tumor microenvironment.

Hepatocellular carcinoma (HCC) tumor microenvironment is more suppressive than colorectal cancer liver metastasis (CRLM) tumor microenvironment.

Journal: Hepatology international
Published: December 27, 2022

CXCR4-CXCL12-CXCR7 and PD-1/PD-L1 in Pancreatic Cancer: CXCL12 Predicts Survival of Radically Resected Patients.

CXCR4-CXCL12-CXCR7 and PD-1/PD-L1 in Pancreatic Cancer: CXCL12 Predicts Survival of Radically Resected Patients.

Journal: Cells
Published: August 04, 2022

Tailoring the Structure of Cell Penetrating DNA and RNA Binding Nucleopeptides.

Tailoring the Structure of Cell Penetrating DNA and RNA Binding Nucleopeptides.

Journal: International journal of molecular sciences
Published: July 14, 2022

Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients.

Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients.

Journal: Cancers
Published: February 10, 2022

In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies.

In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies.

Journal: Journal for immunotherapy of cancer
Published: January 18, 2022

AR-V7 exhibits non-canonical mechanisms of nuclear import and chromatin engagement in castrate-resistant prostate cancer.

AR-V7 exhibits non-canonical mechanisms of nuclear import and chromatin engagement in castrate-resistant prostate cancer.

Journal: eLife
Published: August 27, 2021

CXCL12 Signaling in the Tumor Microenvironment.

CXCL12 Signaling in the Tumor Microenvironment.

Journal: Advances in experimental medicine and biology
Published: July 21, 2021
Showing 1-12 of 36

Last Updated: 09/26/2026